What is Novasight?
Novasight operates at the intersection of ophthalmology and digital therapeutics, specializing in sophisticated eye-tracking and data analytics platforms. Its flagship offerings, CureSight and TrackSight, are engineered to address prevalent pediatric conditions such as amblyopia and myopia. By digitizing the treatment process, the company transforms clinical vision care into an engaging, accessible experience for children. This technological shift not only enhances patient compliance but also provides healthcare practitioners with granular, actionable insights, effectively bridging the gap between clinical assessment and home-based intervention. The company's market position is defined by its commitment to improving long-term vision health outcomes through non-invasive, software-driven medical devices.
How much funding has Novasight raised?
Novasight has raised a total of $8M across 1 funding round:
Series A
$8M
Series A (2020): $8M with participation from Rimonci Capital
Key Investors in Novasight
Rimonci Capital
Rimonci Capital is a venture capital firm focused on identifying and supporting high-growth companies within the healthcare and life sciences sectors.
What's next for Novasight?
With this major enterprise-level funding, Novasight is well-positioned to accelerate its clinical validation efforts and expand its global footprint. The strategic allocation of this capital will likely focus on scaling the deployment of its digital therapeutic suite across international markets and deepening its integration within existing pediatric healthcare ecosystems. As the company transitions into its next phase of growth, the focus will remain on refining its data analytics capabilities to further personalize treatment protocols. By maintaining a rigorous approach to clinical efficacy and user experience, Novasight is poised to set a new standard in pediatric vision management, potentially disrupting traditional care models and establishing a robust, data-centric foundation for future innovations in the broader ophthalmology space.
See full Novasight company page
